Publications by authors named "Piro Lito"

Claim this Profile
B
BRAF-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.
Melanie Angelina Dacheux, Meng-Jung Wu, Michael T Scherzer, Monique Nillson, Brandon Murphy, Piro Lito

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological restoration of GTP hydrolysis by mutant RAS.
Antonio Cuevas-Navarro, Yasin Pourfarjam, Feng Hu, Diego J Rodriguez, Alberto Vides, Piro Lito

Nature· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS Oncoprotein Signaling in Cancer.
Piro Lito

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.
Junya Sango, Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour, Piro Lito

Nature· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of [I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.
Raik Artschwager, Teja M Kalidindi, Delissa Johnson, Christopher Brennan, Zachary V Samuels, Piro Lito

ACS Pharmacol Transl Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling lung adenocarcinoma metastases using patient-derived organoids.
Yuan Liu, Manendra Lankadasari, Joel Rosiene, Kofi E Johnson, Juan Zhou, Piro Lito

Cell Rep Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF lung adenocarcinoma.
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, Sonia San José, Sergio de Hita, Piro Lito

Cell Rep Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Matthew Holderfield, Bianca J Lee, Jingjing Jiang, Aidan Tomlinson, Kyle J Seamon, Piro Lito

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
Feng Hu, Piro Lito

Cancer Cell· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Piro Lito

Future Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Piro Lito

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Christopher J Schulze, Kyle J Seamon, Yulei Zhao, Yu C Yang, Jim Cregg, Piro Lito

Science· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Dongsung Kim, Lorenz Herdeis, Dorothea Rudolph, Yulei Zhao, Jark Böttcher, Piro Lito

Nature· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Piro Lito

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced -Mutant Non-Small Cell Lung Cancer.
Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, Bob T Li, Afsheen Iqbal, Piro Lito

JCO Precis Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The KRYSTAL-1 study of adagrasib - a new trial for KRAS-mutated non-small-cell lung cancer.
Yonina R Murciano-Goroff, Piro Lito

Nat Rev Clin Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Justin Jee, Emily S Lebow, Randy Yeh, Jeeban P Das, Azadeh Namakydoust, Piro Lito

Nat Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the Arsenal of Clinically Active G12C Inhibitors.
Kathryn C Arbour, Piro Lito

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune biomarkers and response to checkpoint inhibition of BRAF and BRAF non-V600 altered lung cancers.
Yonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, Jessica R Flynn, Joseph Montecalvo, Piro Lito

Br J Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
With one eye on the future.
Carlos Caldas, Maria Rescigno, Samra Turajlic, Anant Madabhushi, Zemin Zhang, Piro Lito

Cancer Cell· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring Mutations.
Kathryn C Arbour, Eusebio Manchado, Matthew J Bott, Linda Ahn, Yosef Tobi, Piro Lito

JTO Clin Res Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Yulei Zhao, Yonina R Murciano-Goroff, Jenny Y Xue, Agnes Ang, Jessica Lucas, Piro Lito

Nature· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Chuanchuan Li, Alberto Vides, Dongsung Kim, Jenny Y Xue, Yulei Zhao, Piro Lito

Science· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired Resistance to KRAS Inhibition in Cancer.
Mark M Awad, Shengwu Liu, Igor I Rybkin, Kathryn C Arbour, Julien Dilly, Piro Lito

N Engl J Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors.
Yulei Zhao, Jenny Y Xue, Piro Lito

Cancer Discov· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis